Cargando…
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every 8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a...
Autores principales: | Kruit, W. H., Punt, C. J., Goey, S. H., de Mulder, P. H., Gratama, J. W., Eggermont, A. M., Bolhuis, R. L., Stoter, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074736/ https://www.ncbi.nlm.nih.gov/pubmed/8826864 |
Ejemplares similares
-
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
por: Goey, S. H., et al.
Publicado: (1995) -
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995) -
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
por: Goey, S. H., et al.
Publicado: (1996) -
Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)
por: Punt, C. J., et al.
Publicado: (1990) -
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
por: Punt, C. J., et al.
Publicado: (1997)